Abstract
This article reviews recent studies of platinum and other metal-containing antitumor drugs in preclinical development. A short overview of the development of cisplatin-based drug generations is given. Some pioneering strategies towards unconventional drugs, such as platinum complexes with biomolecules and carrier ligands, organoplatinum and multinuclear platinum complexes developed in recent years are outlined. Furthermore, nonplatinum-based antitumor drugs containing ruthenium(II/III), gallium(III), titanium(IV) or tin(IV) that illustrate the prominent strategies are presented with an emphasis on recent developments. In addition, alternatives for water insoluble drugs will be discussed. A brief overview of development of nanodrug delivery systems and their potential as alternative cancerostatic carriers are discussed.
Keywords: Anticancer metallotherapeutics, cisplatin, drug delivery system, gallium(III), liposomes, platinum(II), platinum(IV), nanomaterials, organoplatinum(IV), ruthenium(II), ruthenium(III), tin(IV), titanium(IV), transplatinum complexes
Current Medicinal Chemistry
Title: Anticancer Metallotherapeutics in Preclinical Development
Volume: 18 Issue: 31
Author(s): G. N. Kaluderovic and R. Paschke
Affiliation:
Keywords: Anticancer metallotherapeutics, cisplatin, drug delivery system, gallium(III), liposomes, platinum(II), platinum(IV), nanomaterials, organoplatinum(IV), ruthenium(II), ruthenium(III), tin(IV), titanium(IV), transplatinum complexes
Abstract: This article reviews recent studies of platinum and other metal-containing antitumor drugs in preclinical development. A short overview of the development of cisplatin-based drug generations is given. Some pioneering strategies towards unconventional drugs, such as platinum complexes with biomolecules and carrier ligands, organoplatinum and multinuclear platinum complexes developed in recent years are outlined. Furthermore, nonplatinum-based antitumor drugs containing ruthenium(II/III), gallium(III), titanium(IV) or tin(IV) that illustrate the prominent strategies are presented with an emphasis on recent developments. In addition, alternatives for water insoluble drugs will be discussed. A brief overview of development of nanodrug delivery systems and their potential as alternative cancerostatic carriers are discussed.
Export Options
About this article
Cite this article as:
N. Kaluderovic G. and Paschke R., Anticancer Metallotherapeutics in Preclinical Development, Current Medicinal Chemistry 2011; 18 (31) . https://dx.doi.org/10.2174/092986711797535308
DOI https://dx.doi.org/10.2174/092986711797535308 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of the Oxidative Stress Level and Serum Prolidase Activity in Patients with Sleep Bruxism
Combinatorial Chemistry & High Throughput Screening Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways
Anti-Cancer Agents in Medicinal Chemistry Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Mouse Strains for Prostate Tumorigenesis Based on Genes Altered in Human Prostate Cancer
Current Drug Targets Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma
Current Gene Therapy Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Recent Patents on DNA & Gene Sequences Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry